Concomitant Medications and Risk of Chemotherapy‐Induced Peripheral Neuropathy

• Published in: The oncologist (Dayton, Ohio) Vol. 24; no. 8; pp. e784 - e792
• Main Authors: Sánchez‐Barroso, Lara, Apellaniz‐Ruiz, Maria, Gutiérrez‐Gutiérrez, Gerardo, Santos, María, Roldán‐Romero, Juan M., Curras, Maria, Remacha, Laura, Calsina, Bruna, Calvo, Isabel, Sereno, María, Merino, María, García‐Donas, Jesús, Castelo, Beatriz, Guerra, Eva, Letón, Rocio, Montero‐Conde, Cristina, Cascón, Alberto, Inglada‐Pérez, Lucía, Robledo, Mercedes, Rodríguez‐Antona, Cristina
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-08-2019
• Subjects: Comorbidities; Concomitant medications; Paclitaxel; Peripheral neuropathy; Risk factors; Symptom Management and Supportive Care; Comorbidities; Peripheral neuropathy; Concomitant medications; Risk factors; Paclitaxel
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2018-0418

Background
Peripheral neuropathy is the dose‐limiting toxicity of many oncology drugs, including paclitaxel. There is large interindividual variability in the neuropathy, and several risk factors have been proposed; however, many have not been replicated. Here we present a comprehensive study aimed at identifying treatment and physiopathology‐related paclitaxel‐induced neuropathy risk factors in a large cohort of well‐characterized patients.
Patients and Methods
Analyses included 503 patients with breast or ovarian cancer who received paclitaxel treatment. Paclitaxel dose modifications caused by the neuropathy were extracted from medical records and patients self‐reported neuropathy symptoms were collected. Multivariate logistic regression analyses were performed to identify concomitant medications and comorbidities associated with paclitaxel‐induced neuropathy.
Results
Older patients had higher neuropathy: for each increase of 1 year of age, the risk of dose modifications and grade 3 neuropathy increased 4% and 5%, respectively. Cardiovascular drugs increased the risk of paclitaxel dose reductions (odds ratio [OR], 2.51; p = .006), with a stronger association for beta‐adrenergic antagonists. The total number of concomitant medications also showed an association with dose modifications (OR, 1.25; p = .012 for each concomitant drug increase). A dose modification predictive model that included the new identified factors gave an area under the curve of 0.74 (p = 1.07 × 10−10). Preexisting nerve compression syndromes seemed to increase neuropathy risk.
Conclusion
Baseline characteristics of the patients, including age and concomitant medications, could be used to identify individuals at high risk of neuropathy, personalizing chemotherapy treatment and reducing the risk of severe neuropathy.
Implications for Practice
Peripheral neuropathy is a common adverse effect of many cancer drugs, including chemotherapeutics, targeted therapies, and immune checkpoint inhibitors. About 40% of survivors of cancer have functional deficits caused by this toxicity, some of them irreversible. Currently, there are no effective treatments to prevent or treat this neuropathy. This study, performed in a large cohort of well‐characterized patients homogenously treated with paclitaxel, identified concomitant medications, comorbidities, and demographic factors associated with peripheral neuropathy. These factors could serve to identify patients at high risk of severe neuropathy for whom alternative non‐neurotoxic alternatives may be considered.
Peripheral neuropathy is a common adverse effect of many cancer drugs, including chemotherapeutics, targeted therapies, and immune checkpoint inhibitors. This article reports results of a study designed to identify treatment and physiopathology‐related paclitaxel‐inducd neuropathy risk factors in a cohort of ore than 500 patients.